Showing 109 results
-
Media Release /Novartis has begun collaborating with seven clinics across the province to support the prevention, identification and management of atherosclerotic cardiovascular disease (ASCVD) In Ontario,…
-
Media Release /Fabhalta® is the first oral monotherapy for previously treated and treatment-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH)1,2 Significant unmet need remains in PNH, a chronic, rare…
-
Media Release /Ontario is the first province in Canada to offer public reimbursement for Pluvicto™, a targeted radioligand therapy for patients with progressive PSMA-positive metastatic castration-resistant…
-
Media Release /Targeted radioligand therapy closer to public reimbursement for eligible Canadian patients with PSMA-positive metastatic castration-resistant prostate cancerMontreal, Quebec, December 13, 2024 –…
-
Media Release /The Novartis Health Equity Initiative was launched earlier this year as a call for ideas to help tackle persistent health disparities and promote equal access to healthcare in CanadaSubmissions were…
-
Media Release /Montreal, November 15, 2024 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is extremely disappointed that negotiations for PLUVICTO™ (lutetium (177Lu) vipivotide tetraxetan injection), a…
-
Story /
